DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03881995

Lixibrain01

TerminatedPhase 4

Effects of Insulin Glargine and Lixisenatide on the Brain

Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes

Asset

Lixisenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI 25-45

Primary endpoint

•Brain insulin sensitivity

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03881995
Org study ID808/2018AMG1
Secondary ID2018-003557-21

Timeline

Milestones

Study start2019-03-18actual
Study first posted2019-03-20actual
Primary completion2020-06-29actual
Study completion2020-06-29actual
Last update posted2020-07-10actual

Assets

Investigational agents

Lixisenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Must be between 18 and 65 years at the time of signing the informed consent.
•BMI 25-45 kg/m²
•Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
•Ability to adhere to the study visit schedule and other protocol requirements.
•Patients with type 2 diabetes mellitus diagnosed for at least 1 year before the screening visit (visit 1) treated for at least 3 months prior to visit 1 with only metformin or metformin and a sodium glucose co-transporter 2 inhibitor, and patients who are not adequately controlled with this treatment.
•Females of childbearing potential (FCBP) must agree
–to utilize a highly effective forms of contraception (Pearl index < 1) or practice complete abstinence from heterosexual contact while participating in the study (including dose interruptions), and for at least 28 days after study treatment discontinuation and must agree to pregnancy testing during this timeframe
–to abstain from breastfeeding during study participation and 28 days after study drug discontinuation.
•Males must agree
–to use a latex condom during any sexual contact with FCBP while participating in the study and for 28 days following discontinuation from this study, even if he has undergone a successful vasectomy
–to refrain from donating semen or sperm while participating in this study and for 28 days after discontinuation from this study treatment.
•All subjects must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study treatment.
•All subjects must agree not to share medication.

Exclusion criteria

•HbA1c at screening visit less than 7.5% or more than 12% for patients previously treated with metformin alone or with metformin and a second oral anti-diabetic treatment.
•Women during pregnancy and lactation.
•History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal products. This includes iGlarLixi, insulin glargine, and human nasal insulin.
•Use of oral glucose-lowering agents other than those stated in the inclusion criteria or any injectable glucose-lowering agents during 3 months before screening
•History of discontinuation of a previous treatment with a GLP-1 receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.
•Patient who has previously participated in any clinical trial with lixisenatide or the insulin glargine + lixisenatide fixed ratio combination or has previously received lixisenatide.
•Any contraindication to metformin use, according to local labeling.
•Use of weight loss drugs within 3 months prior to screening visit.
•Within the last 6 months prior to screening visit: myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.
•History of stroke.
•History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.
•Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
•Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 160 mmHg or diastolic blood pressure above 90 mmHg) at screening visit.
•At screening visit, Body Mass Index (BMI) less than or equal to 25 or above 45 kg/m².
•At screening visit ALT or AST more than 3 ULN.
•At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
•Exclusion Criteria for randomization at the end of the screening period:
–HbA1c less than 7.5% or above 12%.
–Amylase and/or lipase more than 3 ULN.
–Calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
•Participation in other clinical trials or observation period of competing trials up to 30 days prior to this study.
•Known malformation of the central nervous system
•Persons working nightshift
•Treatment with drugs with central nervous actions or systemic steroid therapy
•Any relevant (according to investigator's judgment) cardiovascular disease, e.g. myocardial infarction, acute coronary syndrome, unstable angina pectoris, PTCA, heart failure (NYHA II-IV), planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.
•Indication of liver disease, as per medical history or defined by serum levels of either Alanine Aminotransferase (ALT [SGPT]), Aspartate Aminotransferase (AST [SGOT]), or Alkaline Phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
•Alcohol abuse, defined as more than 20 gr/day
•Impaired renal function, defined as estimated Glomerular Filtration Rate (eGFR) ≤ 60 ml/min (MDRD formula) as determined during screening.
•Known structural and functional urogenital abnormalities that that predispose for urogenital infections.
•Subjects with a haemoglobin (Hb) between 14 and 18 g/dl (for males) and Hb between 12 and 16 g/dl (for females) at screening.
•Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption within the last 5 years.
•Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
•Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.
•Known autoimmune disease (except autoimmune disease of the thyroid gland) or chronic inflammatory condition.
•Claustrophobia
•Any other clinically significant major organ system disease at screening such as relevant gastrointestinal, neurologic, psychiatric, endocrine (i.e. pancreatic), hematologic, malignant, infection or other major systemic diseases making implementation of the protocol or interpretation of the study results difficult.
•Presence of any contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.
•Any other clinical condition that would jeopardize subjects' safety while participating in this clinical trial.
•Refusal to get informed of unexpected detected pathological MRI findings
•History of diabetic ketoacidosis
•Severe gastric or bowel disease (including gastroparesis)

Endpoints (19)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
8
Weight & body composition
6
Safety / tolerability / PK
2
Glycemic / diabetes
1
MASH / liver
1
Other (unclassified)
1

Weight & body composition

6 endpoints
Secondary/protocol endpoint

Total adipose tissue (TAT)

Time frame:Change from baseline body fat distribution at 12 weeks

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Visceral adipose tissue (VAT)

Time frame:Change from baseline body fat distribution at 12 weeks

Visceral fat, change

change from baseline, improvement

Secondary/protocol endpoint

Subcutaneous adipose tissue (SCAT)

Time frame:Change from baseline body fat distribution at 12 weeks

Subcutaneous fat, change

change from baseline, improvement

Secondary/protocol endpoint

Body fat

Time frame:Change from baseline body fat at 12 weeks

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Lean body mass

Time frame:Change from baseline body fat at 12 weeks

Lean mass

change from baseline, improvement

Secondary/protocol endpoint

Body weight

Time frame:Change from baseline body weight at 12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Glycemic control

Time frame:Change from baseline glycemic control at 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

1 endpoint
Secondary/protocol endpoint

Liver fat content

Time frame:Change from baseline body fat distribution at 12 weeks

Liver fat content, change

change from baseline, improvement

Safety / tolerability / PK

2 endpoints
Other/protocol endpoint

Hypoglycemia

Time frame:1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks after randomisation

Documented hypoglycemia

event count, event

Other/protocol endpoint

Hypoglycemia time of day

Time frame:1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks after randomisation

descriptive

Other clinical outcomes

8 endpoints
Secondary/protocol endpoint/low confidence

Processing of food pictures

Time frame:Change from baseline processing of food pictures at 12 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Cognitive function

Time frame:Change from baseline participant's speed of response and the accuracy of pointing at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Cognitive function

Time frame:Change from baseline reaction time and movement time at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Cognitive function

Time frame:Change from baseline latency, probability of false alarms and sensitivity at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Cognitive function

Time frame:Change from errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores and stages completed baseline at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Cognitive function

Time frame:Change from baseline errors and strategy at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Cognitive function

Time frame:Change from baseline number and percentage of correct trials and latency at 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Cognitive function

Time frame:Change from baseline latency, the number of correct patterns selected and a statistical measure giving the probability of an error after a correct or incorrect response at 12 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Brain insulin sensitivity

Time frame:Change from baseline brain insulin sensitivity at 12 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.